Efficacy of N-acetylcysteine in patients with COVID-19

Evaluation of the efficacy and safety of oral N-acetylcysteine in treatment and recovery of patients with COVID-19 who are under treatment with routine protocols

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200623047897N1

Enrollment

Registered

2020-08-16

Start date

2020-05-21

Completion date

Unknown

Last updated

2020-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

covid-19. COVID-19

Interventions

Intervention 1: Intervention group: hospitalized patients with moderate-sever covid-19 with stable vital signs who receive NAC.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: admitted patients with COVID-19 moderate to severe, stable patients

Exclusion criteria

Exclusion criteria: unstable and intubated ICU patients pregnancy, breastfeeding infancy allergy and intolerance to NAC unstable vital signs or need for intubation

Design outcomes

Primary

Measure	Time frame
Time to improve symptoms such as cough, shortness of breath and lethargy. Timepoint: At the beginning of the hospitalization/ two weeks after treatment. Method of measurement: clinical evaluation.;O2 saturation. Timepoint: At the beginning of the hospitalization/ two weeks after treatment. Method of measurement: clinical evaluation and pulse oximetery.;Re-hospitalization after discharge. Timepoint: At the beginning of the hospitalization/ two weeks after treatment. Method of measurement: clinical evaluation.;Duration of hospitalization. Timepoint: after discharge. Method of measurement: days.;Evaluation of laboratory parameters as a series of factors: PCR and LDH, CBC, ESR, CRP Comparison of parameters at the beginning of hospitalization, during hospitalization and at the time of discharge. Timepoint: At the beginning of the hospitalization/ during hospitalization/ at discharge time. Method of measurement: lab data analysis.;Check for changes in anti-inflammatory parameters (TNF-ALPHA and IL-6 if measuring kits are available). Timepoint: At the beginning of the hospitalization/ at discharge time. Method of measurement: lab data analysis.;Investigation of radiological changes at the beginning of hospitalization and during hospitalization if possible. Timepoint: At the beginning of the hospitalization/ during hospitalization. Method of measurement: radiographic changes.;ICU admission. Timepoint: during hospitalization. Method of measurement: clinical evaluation.;Recovery or death. Timepoint: during hospitalization and after discharge. Method of measurement: clinical evaluation.	—

Measure

Time frame

Time to improve symptoms such as cough, shortness of breath and lethargy. Timepoint: At the beginning of the hospitalization/ two weeks after treatment. Method of measurement: clinical evaluation.;O2 saturation. Timepoint: At the beginning of the hospitalization/ two weeks after treatment. Method of measurement: clinical evaluation and pulse oximetery.;Re-hospitalization after discharge. Timepoint: At the beginning of the hospitalization/ two weeks after treatment. Method of measurement: clinical evaluation.;Duration of hospitalization. Timepoint: after discharge. Method of measurement: days.;Evaluation of laboratory parameters as a series of factors: PCR and LDH, CBC, ESR, CRP Comparison of parameters at the beginning of hospitalization, during hospitalization and at the time of discharge. Timepoint: At the beginning of the hospitalization/ during hospitalization/ at discharge time. Method of measurement: lab data analysis.;Check for changes in anti-inflammatory parameters (TNF-ALPHA and IL-6 if measuring kits are available). Timepoint: At the beginning of the hospitalization/ at discharge time. Method of measurement: lab data analysis.;Investigation of radiological changes at the beginning of hospitalization and during hospitalization if possible. Timepoint: At the beginning of the hospitalization/ during hospitalization. Method of measurement: radiographic changes.;ICU admission. Timepoint: during hospitalization. Method of measurement: clinical evaluation.;Recovery or death. Timepoint: during hospitalization and after discharge. Method of measurement: clinical evaluation.

—

Secondary

Measure	Time frame
Side effects. Timepoint: Time to start the intervention/ during hospitalization, two weeks after interventions. Method of measurement: Clinical, laboratory evaluation.;Need change initial treatment or add new drug to the regimen. Timepoint: during hospitalization. Method of measurement: clinical assessment.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNajmolsadat Atefi

Iran University of Medical Sciences

atefi.ns@iums.ac.ir00982164351

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026